Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic Mutation”

8 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 8 of 8 results

Testing effectiveness (Phase 2)UnknownNCT04556292
What this trial is testing

A Phase II Study to Assess the Efficacy and Safety of SC10914 in the Metastatic Breast Cancer Patients

Who this might be right for
Breast Cancer MetastaticBRCA 1 Gene MutationBRCA 2 Gene Mutation
Jiangxi Qingfeng Pharmaceutical Co. Ltd. 78
Testing effectiveness (Phase 2)Study completedNCT00664781
What this trial is testing

Rucaparib(CO-338;Formally Called AG-014699 or PF-0136738) in Treating Patients With Locally Advanced or Metastatic Breast Cancer or Advanced Ovarian Cancer

Who this might be right for
brca1 Mutation Carrierbrca2 Mutation CarrierBreast Cancer+1 more
Cancer Research UK 78
Testing effectiveness (Phase 2)Study completedNCT01506609
What this trial is testing

Study Evaluating Efficacy And Tolerability Of Veliparib in Combination With Temozolomide (TMZ) or In Combination With Carboplatin and Paclitaxel Versus Placebo in Participants With Breast Cancer Gene (BRCA)1 and BRCA2 Mutation and Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer
AbbVie 294
Not applicableLooking for participantsNCT05378204
What this trial is testing

Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.

Who this might be right for
Breast Cancer
Institut Claudius Regaud 120
Testing effectiveness (Phase 2)Ended earlyNCT02034916
What this trial is testing

A Phase 2, 2-Stage, 2-Cohort Study of Talazoparib (BMN 673), in Locally Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (ABRAZO Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 84
Not applicableNo Longer AvailableNCT02985658
What this trial is testing

Expanded Access With ABT-888 (Veliparib) to Treat Metastatic Breast Cancer

Who this might be right for
Metastatic Breast Cancer With BRCA 1 or BRCA 2 Genetic MutationTriple-Negative Breast Cancer
University of Washington
Early research (Phase 1)Ended earlyNCT05252390
What this trial is testing

NUV-868 as Monotherapy and in Combination With Olaparib or Enzalutamide in Adult Patients With Advanced Solid Tumors

Who this might be right for
Advanced Solid TumorOvarian CancerOvary Cancer+24 more
Nuvation Bio Inc. 82
Large-scale testing (Phase 3)Study completedNCT01945775
What this trial is testing

A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)

Who this might be right for
Breast NeoplasmsBRCA 1 Gene MutationBRCA 2 Gene Mutation
Pfizer 431